Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy.
Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Cancer Cell. 2020 Nov 9;38(5):624-625. doi: 10.1016/j.ccell.2020.10.019.
A recent study in The Lancet Oncology reports that high tumor mutational burden (TMB) is associated with response to anti-PD-1 pembrolizumab, leading to the second FDA approval of a tissue-agnostic predictive biomarker for immunotherapy in solid tumors. This is a step forward in realizing the full potential of cancer immunotherapy.
《柳叶刀肿瘤学》的一项最新研究报告称，高肿瘤突变负担（TMB）与抗 PD-1 派姆单抗的应答相关，这导致了第二个 FDA 批准的实体瘤免疫治疗的组织不可知预测性生物标志物。这是在实现癌症免疫治疗的全部潜力方面迈出的一步。
